Mostrar el registro sencillo

dc.contributor.authorArboleya, Luises_ES
dc.contributor.authorCancio-Trujillo, José Manueles_ES
dc.contributor.authorChaves, Celiaes_ES
dc.contributor.authorDuaso-Magaña, Enrices_ES
dc.contributor.authorMesa-Ramos, Manueles_ES
dc.contributor.authorOlmos Martínez, José Manuel es_ES
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2023-11-07T18:58:58Z
dc.date.available2023-11-07T18:58:58Z
dc.date.issued2023es_ES
dc.identifier.issn1862-3522es_ES
dc.identifier.issn1862-3514es_ES
dc.identifier.urihttps://hdl.handle.net/10902/30595
dc.description.abstractSummary The OSARIDELPHI study evaluated the level of agreement between specialists in osteoporosis regarding the management of patients with high-risk fractures in Spain. The results provide expert-based recommendations for prevention, diagnosis, and treatment related to fracture risk. Therefore, the study facilitates clinical decision-making for managing this patient's profile. Purpose To evaluate the level of agreement between specialists in osteoporosis regarding the management of patients with high-risk fractures in Spain. Methods A two-round Delphi study was performed using an online survey. In round 1, panel members rated their level of agreement with assessments on a 9-point Likert scale. Item selection was based on acceptance by ≥ 66.6% of panel experts and the agreement of the scientific committee. In round 2, the same panelists evaluated non-consensus items in round 1. Results A total of 80 panelists participated in round 1; of these, 78 completed the round 2 survey. In round 1, 122 items from 4 dimensions (definition of fracture risk: 11 items, prevention and diagnosis: 38 items, choice of treatment: 24 items, and treatment-associated quality of life: 49 items) were evaluated. The consensus was reached for 90 items (73.8%). Panelists agreed that categorizing high risk, very high risk, or imminent risk determines secondary prevention actions (97.5%). Experts agreed that treatment with bone-forming drugs should be considered in case of a very high risk of fracture, and a sequential change to antiresorptive drugs should be made after 1-2 years (97.5%). Panelists also recommended corrective action plans for non-adherent patients to improve adherence (97.5%). A total of 131 items were finally accepted after round 2. Conclusion This Delphi study provides expert-based recommendations on clinical decision-making for managing patients with osteoporosis at high risk of fracture.es_ES
dc.description.sponsorshipFunding. This study was sponsored by STADA. Acknowledgements. The authors acknowledge Lola Andreu-Pérez and Alicia Subtil-Rodríguez (both from Evidenze Clinical Research) for project coordination and editorial assistance based on the authors’ input.es_ES
dc.format.extent9 p.es_ES
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.rightsAttribution 4.0 International*
dc.rights© The Author(s) 2023es_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceArchives of Osteoporosis, 2023, 18, 110es_ES
dc.subject.otherConsensuses_ES
dc.subject.otherDelphi methodes_ES
dc.subject.otherOsteoporosises_ES
dc.subject.otherHigh-risk fracturees_ES
dc.subject.otherTreatmentes_ES
dc.subject.otherFracture-liaison service (FLS) unites_ES
dc.titleA Delphi consensus on the management of spanish patients with osteoporosis at high risk of fracture: OSARIDELPHI studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsopenAccesses_ES
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Attribution 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International